source
- Roche commits up to $1 billion to develop bispecific antibodies with DualitasRoche announced a partnership with Dualitas Therapeutics, a California biotech, to advance bispecific antibody programs aimed at immunological and inflammatory diseases. The agreement includes an…
- Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival EndpointSellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…